Details

Autor(en) / Beteiligte

• Køber, Lars
• Torp-Pedersen, Christian
• McMurray, John J.V
• Gøtzsche, Ole
• Lévy, Samuel
• Crijns, Harry
• Amlie, Jan
• Carlsen, Jan

Titel

Increased Mortality after Dronedarone Therapy for Severe Heart Failure

Ist Teil von

• The New England journal of medicine, 2008-06, Vol.358 (25), p.2678-2687

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2008

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Dronedarone is a class III antiarrhythmic drug that has efficacy as a treatment for atrial fibrillation and ventricular arrhythmias. In this clinical trial involving patients with severe heart failure, however, dronedarone was found to increase overall mortality, raising serious concern about the safety of this drug in patients with advanced heart failure. In patients with severe heart failure, dronedarone was found to increase overall mortality, raising serious concern about the safety of this drug in patients with advanced heart failure. Atrial and ventricular arrhythmias contribute to the morbidity and mortality associated with heart failure. 1 – 3 Class III antiarrhythmic agents reduce the likelihood of the development of atrial fibrillation in patients with heart failure and also increase the rate of conversion from atrial fibrillation to sinus rhythm, which may reduce the risk of acute decompensation. In a previous randomized trial involving patients with heart failure, use of one agent in this class, dofetilide, was associated with fewer hospitalizations for worsening heart failure. 4 Ventricular arrhythmias are also common in patients with heart failure and reduced systolic function and frequently lead to sudden . . .